Objective: To evaluate Kisspeptin-10 (Kiss-10) in patients with small renal tumours (SRTs) and controls. Material and Methods: Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit. The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas. Results: Kiss-10 was detected in all patients and controls. SRT patients revealed significantly higher Kiss-10 levels than controls (mean value 10.04 vs. 6.37 pmol/l, p < 0.001). In SRT patients, Kiss-10 was detected at significantly different concentrations between the subgroups (p = 0.021). The highest concentration was observed in those with oncocytomas (11.50 pmol/) followed by chRCC, pRCC and ccRCC patients (9.89, 10.01 and 9.25 pmol/l, respectively). Receiver operating characteristic curve analyses revealed an area under the curve (AUC) of 0.82 for the comparison of all tumours vs. controls (p < 0.001) and an AUC of 0.671 for all malignant tumours vs. oncoytomas (p = 0.003). Conclusion: This study shows that Kiss-10 levels are significantly altered by malignancy and tumour subtypes even in patients with SRTs. Kiss-10 therefore deserves further attention as a plasmatic biomarker for renal tumours.

Keywords:
Small renal tumours, Kisspeptin-10, Kiss-1 Gene, Tumour subtypes
1.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Rising incidence of small renal masses: a need to reassess treatment effect. JNCI J Natl Cancer Inst 2006;98:1331-1334.
2.
Borghesi M, Brunocilla E, Volpe A, Dababneh H, Pultrone CV, Vagnoni V, La Manna G, Porreca A, Martorana G, Schiavina R: Active surveillance for clinically localized renal tumors: an updated review of current indications and clinical outcomes. Int J Urol 2015;22:432-438.
3.
Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG: The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175:425-431.
4.
Schiavina R, Borghesi M, Dababneh H, Bianchi L, Longhi B, Diazzi D, Monti C, La Manna G, Martorana G, Brunocilla E: Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up. Clin Genitourin Cancer 2015;13:e87-e92.
5.
Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, Chromecki T, Jesche-Chromecki J, Fisch M, Zigeuner R, et al: The adoption of nephron-sparing surgery in Europe - a trend analysis in two referral centers from Austria and Germany. Urol Int 2016;96:330-336.
6.
Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ, Remzi M, Uzzo RG: Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 2012;62:491-504.
7.
Prabhu VV, Sakthivel KM, Guruvayoorappan C: Kisspeptins (KiSS-1): essential players in suppressing tumor metastasis. Asian Pac J Cancer Prev 2013;14:6215-6220.
8.
Ji K, Ye L, Mason MD, Jiang WG: The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (review). Int J Mol Med 2013;32:747-754.
9.
Squillacciotti S, Kraemer K, Fuessel S, Meinhardt M, Zastrow S, Grimm M, Tubaro A, Wirth M: Plasmatic Metastin, Kisspeptin, and Kiss1R tissue expression as biomarkers in clear cell renal cell carcinoma (CCRCC). J Urol 2011;185:e156-e157.
10.
Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88:1731-1737.
11.
Dhillo W: Timeline: kisspeptins. Lancet Diabetes Endocrinol 2013;1:12-13.
12.
Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, Brezillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, et al: The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 2001;276:34631-34636.
13.
Horikoshi Y, Matsumoto H, Takatsu Y, Ohtaki T, Kitada C, Usuki S, Fujino M: Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003;88:914-919.
14.
Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W, et al: Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004;117(pt 8):1319-1328.
15.
Murray MJ, Lessey BA: Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Semin Reprod Endocrinol 1999;17:275-290.
16.
Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, Masui T, Kawaguchi Y, Tomita K, Oishi S, et al: Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 2009;28:9.
17.
Ikeguchi M, Yamaguchi K, Kaibara N: Clinical significance of the loss of KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:1379-1383.
18.
Katagiri F, Nagai K, Kida A, Tomita K, Oishi S, Takeyama M, Doi R, Fujii N: Clinical significance of plasma metastin level in pancreatic cancer patients. Oncol Rep 2009;21:815-819.
19.
Cvetkovic D, Babwah AV, Bhattacharya M: Kisspeptin/KISS1R system in breast cancer. J Cancer 2013;4:653-661.
20.
Makri A, Pissimissis N, Lembessis P, Polychronakos C, Koutsilieris M: The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer Treatment Rev 2008;34:682-692.
21.
Canbay E, Ergen A, Bugra D, Yamaner S, Eraltan IY, Buyukuncu Y, Bulut T: Kisspeptin-54 levels are increased in patients with colorectal cancer. World J Surg 2012;36:2218-2224.
22.
Ergen A, Canbay E, Bugra D, Zeybek U, Yamaner S, Bulut T: Plasma Kisspeptin-54 levels in gastric cancer patients. Int J Surg 2012;10:551-554.
23.
Shoji S, Tang XY, Umemura S, Itoh J, Takekoshi S, Shima M, Usui Y, Nagata Y, Uchida T, Osamura RY, et al: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol 2009;55:441-449.
24.
Pinthus J: Editorial comment on: metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol 2009;55:450-451.
25.
Chen Y, Yusenko MV, Kovacs G: Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas. J Pathol 2011;223:46-53.
26.
Ramachandran R, Patterson M, Murphy KG, Dhillo WS, Patel S, Kazarian A, Ghatei MA, Bloom SR: Preanalytical factors affecting RIA measurement of plasma kisspeptin. Clin Chem 2008;54:615-617.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.